Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …

Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …

CD33 is a suitable target to guide delivery of a toxic moiety to most acute myeloid leukemia
cells. Gemtuzumab ozogamicin (Mylotarg®) is a humanized antiCD33 monoclonal antibody …

Gemtuzumab ozogamicin (Mylotarg®) is an immunoconjugate composed of a recombinant
humanized murine anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. The …

Gemtuzumab ozogamicin (Mylotarg®) is a conjugate of a monoclonal antibody and
calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid …

Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …

CD33 is expressed by acute myeloid leukemia (AML) cells in> 80% of patients but not by
normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be …

Introduction: Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …

Gemtuzumab ozogamicin (CMA-676, Mylotarg®), an antibody-targeted chemotherapy
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …

Abstract Gemtuzumab Ozogamicin (GO, CMA-676) is a monoclonal antibody against the
cellular surface antigen CD33 conjugated with the cytotoxic antibiotic calicheamicin. In the …